SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction as a cryptocurrency merging blockchain with cannabis culture, sparking interest in its potential for growth and innovation. Community members are actively sharing contract addresses and celebrating the coin's unique identity. The coin is presented as more than just a currency, but a movement towards freedom and cultural expression within the digital space.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community anticipates a potential surge driven by the historical performance of "Uptober" and speculation around pending ETF approvals. Discussions also highlight the potential impact of the government shutdown, with some viewing Bitcoin as a safe haven amid economic uncertainty. Some users are highlighting specific crypto stocks to watch for potential growth.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Conversations around DJT are currently focused on the U.S. government shutdown and its potential impact, with community members debating which party is responsible. Some are discussing Trump's recent statements and actions, including those related to the military and trade, and how they might affect the stock. There's also discussion around the proposed TrumpRx initiative and its potential impact on the pharmaceutical industry.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as a government shutdown looms, sparking debate about its potential impact on the market. While some community members anticipate a market dip and are buying puts, others point to historical data suggesting shutdowns often lead to market rallies. Lithium stocks may see a boost due to government loans.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the crypto market anticipates a potentially bullish "Uptober," with community members eyeing targets around $4500 and beyond. Talk centers around the potential for a short squeeze, with some pointing to Tom Lee's long-term price predictions and recent treasury activity as bullish catalysts. However, some traders remain cautious, citing technical indicators and potential pullbacks amid broader market uncertainty.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending amid positive sentiment around Ethereum, with the community anticipating a potential rally and discussing the company's growing ETH holdings. Talk of a government shutdown and its potential impact on crypto is circulating, with some expecting BMNR to benefit. Technical analysis and predictions of significant price increases are also contributing to the heightened interest.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending due to an upgrade from Jefferies, sparking debate among investors regarding its valuation and business model. Community discussions revolve around the sustainability of Carvana's subprime loan model amid rising delinquencies and broader concerns about the used car market. Some traders are also noting the potential for a short squeeze.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending following the release of its Q1 earnings report, which showed a surprise rise in revenue and beat expectations, signaling that the company's turnaround efforts are gaining traction. Despite positive results, concerns remain around weakness in China and the impact of tariffs, leading to mixed sentiment among investors. The community is actively discussing whether the positive earnings will hold, with some anticipating a move towards $80 and others expecting a pullback due to broader market conditions and concerns about guidance.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the possibility of a government shutdown looms, with the community debating its potential market impact. While some anticipate a downturn, others believe the shutdown's effects are already priced in or view it as a catalyst for a rally. Some traders are closely monitoring technical levels and option activity, while others express concerns about broader economic issues and market manipulation.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto community discusses potential catalysts for a price surge in October, including speculation around ETF approvals and the impact of a possible government shutdown. Some traders are weighing short-term bearish possibilities against the longer term outlook. Community members are also analyzing XRP's relationship with broader crypto market trends and developments with SWIFT.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The U.S. Food and Drug Administration (FDA) announced on Thursday that it is withdrawing its approval of the new drug application (NDA) for Amylyx Pharmaceuticals’ (AMLX) Relyvrio.Amylyx has voluntarily requested that the FDA withdraw approval of this application and has waived its opportunity for a hearing, the agency <a target="_blank" rel="noopener noreferrer nofollow" href="https://public-inspection.federalregister.gov/2025-16646.pdf">said</a>. The FDA approved the application for Relyvrio for the treatment of amyotrophic lateral sclerosis (ALS) in adults in September 2022. Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a progressive, fatal neurodegenerative disorder that causes muscle weakness and paralysis by destroying motor neurons, the cells that control voluntary muscle movement.&nbsp;However, last year, the company reported to the agency that a late-stage trial evaluating the drug in patients living with ALS did not meet its prespecified goals. It also notified the agency that it plans to discontinue marketing of Relyvrio as of Oct. 31, 2024.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AMLX">AMLX stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels. Shares of the company traded 1% lower at the time of writing.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_2_17_49_PM_png_ec4ad4caa5.webp" alt="AMLX's Sentiment Meter and Message Volume as of 2:18 p.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>AMLX's Sentiment Meter and Message Volume as of 2:18 p.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company <a href="https://stocktwits.com/news-articles/markets/equity/amylyx-discontinues-investigative-therapy-program-in-rare-neurological-disorder/chsUG7LRdkv">reiterated</a> earlier this week that it has a cash runway until the end of 2026 on the heels of discontinuing its AMX0035 program in adults living with progressive supranuclear palsy.The decision to discontinue the program was made after it failed to show differences compared to the placebo on primary or secondary outcomes at week 24 in a mid-stage trial. The company will not initiate the late-stage portion of the program, it then said.AMLX stock is up 148% this year and approximately 349% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/li-auto-announces-lower-q3-delivery-outlook-despite-new-vehicle-launches/chs60e1RdZ2">Li Auto Announces Lower Q3 Delivery Outlook Despite New Vehicle Launches: Retail Sees i8, i6 Selling Like ‘Hot Cakes’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target

Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a cash runway until the end of 2026.

Equity

Amylyx Pharmaceuticals Inc. (AMLX) on Wednesday said that it is discontinuing its AMX0035 program in adults living with progressive supranuclear palsy.AMX0035 is an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol. The decision to discontinue the program was made after it failed to show differences compared to the placebo on primary or secondary outcomes at week 24 in a mid-stage trial. The company will not initiate the late-stage portion of the program, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-discontinue-orion-program-amx0035">said</a>.Progressive Supranuclear Palsy (PSP) is a rare, progressive neurological disorder characterized by problems with balance, eye movements, speech, and swallowing, often leading to frequent and unpredictable falls. According to Amylyx, the disease affects about seven in 100,000 people worldwide.On Stocktwits, retail sentiment around the <a href="https://stocktwits.com/symbol/AMLX">AMLX stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels. Shares of the company are down by 2% in the pre-market session.“While we are disappointed in these results, we believe these data will inform the PSP trial literature as well as deepen scientific understanding of this devastating disease,” said Camille L Bedrosian, Chief Medical Officer at Amylyx.Co-CEOs of Amylyx, Joshua Cohen and Justin Klee, said that the company’s priority remains on the late-stage trial of Avexitide, with enrollment expected to be completed in 2025 and topline data anticipated in the first half of 2026.Avexitide is an investigational, glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism.The company is also continuing development of AMX0035 in Wolfram syndrome, a rare, inherited genetic disorder, they said. Amylyx continues to expect its cash runway to extend through the end of 2026.AMLX stock is up by 142% this year and has jumped 330% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-recalls-nearly-356000-vehicles-in-us/chsUG1SRdkx">Ford Issues Nearly 356,000 Vehicles Recall In U.S., But Retail Investors Spot Emerging Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder

The decision to discontinue the program was made after AMX0035 did not show differences compared to placebo on primary or secondary outcomes at week 24 in a mid-stage trial.

Amylyx Pharmaceuticals&nbsp;drew increased retail attention late Sunday after new clinical data presented at ENDO 2025 highlighted the potential of its lead candidate, avexitide, to significantly reduce dangerous blood sugar drops in patients with post-bariatric hypoglycemia (PBH).In a Phase 2b trial, avexitide 90 mg once daily, the dose being studied in the pivotal Phase 3 Lucidity trial, led to a 64% least-squares mean reduction in the composite rate of Level 2 and Level 3 hypoglycemic events.&nbsp;More than half of the participants experienced no severe events during the treatment period.Avexitide is a treatment being developed for post-bariatric hypoglycemia, a condition that currently has no approved therapies. Backed by FDA Breakthrough Therapy designation, the once-daily pill is designed to block the GLP-1 receptor and help prevent dangerous blood sugar drops.&nbsp;New data shared at ENDO 2025 showed that the 90 mg dose maintained steady, around-the-clock activity.&nbsp;A Phase 3 study called Lucidity is now underway, with plans to enroll about 75 people who’ve previously undergone gastric bypass surgery.&nbsp;Amylyx expects to finish signing up participants in 2025 and release the results in the first half of 2026.The data and trial momentum come amid fresh bullish coverage from Wall Street.&nbsp;Goldman Sachs resumed coverage on Amylyx with a ‘Buy’ rating and $10 price target, citing avexitide’s "blockbuster" potential.&nbsp;Guggenheim also started coverage last month with a ‘Buy’ and a $17 target, calling PBH a “not-so-rare” endocrine disease with 50,000–100,000 moderate-to-severe patients in the U.S.&nbsp;Citi joined with a ‘Buy’ and $12 target, highlighting multiple late-stage programs and "clear" clinical endpoints across four high-unmet-need indications.On Stocktwits, retail sentiment for Amylyx was ‘bullish’ amid ‘high’ message volume.Amylyx’s stock has risen 96.4% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crinetics-pharma-s-oral-drug-shows-lasting-relief-for-acromegaly-patients-in-latest-study-retail-buzz-builds/ch8B1oBR5Nq">Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Amylyx Pharmaceuticals (AMLX) highlighted the potential of its lead candidate avexitide to significantly reduce dangerous blood sugar drops in patients with post-bariatric hypoglycemia. (Photo credit: Getty Images)

Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial

The company is advancing the treatment into a Phase 3 study with results expected in 2026. 

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will participate in the following upcoming investor conferences, which are being conducted...

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025. Amylyx senior management team will...

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that Amylyx management will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference. The...

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial...

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering price...

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.45	--	--	N/A
Q2 '25	-$0.44	-$0.46	-3.50%	MISSED
Q1 '25	-$0.47	-$0.42	11.58%	BEAT
Q4 '24	-$0.52	-$0.55	-5.77%	MISSED
Q3 '24	-$0.70	-$1.07	-51.99%	MISSED

AMLX
Amylyx Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest AMLX News

AMLX Amylyx Pharmaceuticals Inc